HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-09-0087v1 16/4/1103    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Vigneri, P. Articles by Vigneri, R. Search for Related Content PubMed PubMed Citation Articles by Vigneri, P. Articles by Vigneri, R.

¹ Section of General Pathology, Department of Biomedical Sciences
² Section of Endocrinology, Department of Internal and Specialistic Medicine, Garibaldi-Nesima Hospital, University of Catania, 95122 Catania, Italy

(Correspondence should be addressed to R Vigneri; Email: vigneri{at}unict.it)

Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases. Because of their frequency, reciprocal influences – even minor influences – may have a major impact. Epidemiological studies clearly indicate that the risk of several types of cancer (including pancreas, liver, breast, colorectal, urinary tract, and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased. Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy, and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and anti-androgens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors. In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.

This article has been cited by other articles:

				E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee Diabetes and Cancer: A consensus report Diabetes Care, July 1, 2010; 33(7): 1674 - 1685. [Full Text] [PDF]

				E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee Diabetes and Cancer: A Consensus Report CA Cancer J Clin, July 1, 2010; 60(4): 207 - 221. [Abstract] [Full Text] [PDF]

				K. Hemminki, X. Li, J. Sundquist, and K. Sundquist Risk of Cancer Following Hospitalization for Type 2 Diabetes Oncologist, June 1, 2010; 15(6): 548 - 555. [Abstract] [Full Text] [PDF]

				H. C. Gerstein Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers? JAMA, February 3, 2010; 303(5): 446 - 447. [Full Text] [PDF]

				C. R. Chong and B. A. Chabner Mysterious Metformin Oncologist, December 1, 2009; 14(12): 1178 - 1181. [Full Text] [PDF]